Purpose: To evaluate the intraocular pressure (IOP) lowering efficacy and safety of Brinzolamide combined with Betaxolol for the Chinese glaucomatous patients.
Methods: Twenty-six glaucoma patients (44 eyes) diagnosed as primary open angle glaucoma, ocular hypertension and remnant glaucoma (IOP remained high after antiglaucomatous surgeries) were recruited as a research team. After a washing out phase, Brinzolamide 1% combined with Betaxolol 0.25% were administered to them twice daily [(8 +/- 1) o'clock in the morning and (20 +/- 1) o'clock in the evening] respectively. The observing duration was 2 months. The IOP and the side effect before and after the administration of the eyedrops were observed.
Results: The average IOP lowering ranged from 5.03 mm Hg to 6.65 mm Hg (1 mm Hg = 0.133 kPa) (20.55% to 37.30%) after the administration of Brinzolamide 1% combined with Betamolol 0.25% twice a day. The IOP lowering effect was stable and the patients complained little uncomfortable.
Conclusions: Brinzolamide combined with Betaxolol has significant IOP lowering effect and few side effect for the Chinese people. Brinzolamide can be used as the main medication for the treatment of glaucoma.